Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENTS
View the documentINTRODUCTION
close this folderStandard Treatment Guidelines (STG)
Open this folder and view contents1. GASTROINTESTINAL CONDITIONS
Open this folder and view contents2. RESPIRATORY DISEASES
Open this folder and view contents3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
Open this folder and view contents4. CARDIOVASCULAR DISEASES
Open this folder and view contents5. MALARIA
Open this folder and view contents6. SKIN DISEASES
Open this folder and view contents7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
Open this folder and view contents8. DENTAL AND ORAL CONDITIONS
Open this folder and view contents9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
Open this folder and view contents10. EAR, NOSE AND THROAT CONDITIONS
Open this folder and view contents11. EYE CONDITIONS
close this folder12. TUBERCULOSIS AND LEPROSY
Open this folder and view contents12.1 Tuberculosis
close this folder12.2 Leprosy
close this folder12.2.1 General Information about Leprosy
View the document12.2.1.1 When Leprosy Should be Suspected
View the document12.2.1.2 Diagnosis of Leprosy
Open this folder and view contents12.2.2 Classification of Leprosy
Open this folder and view contents12.3 Treatment of Leprosy
View the document12.4 Prevention of Disabilities and rehabilitation
Open this folder and view contents12.5 Signs and Treatment of Severe Reversal Reaction (RR)
View the document12.6 Responsibilities
View the document12.7 How to Look After Ulcers
View the document12.8 Surveillance of Patients After Release from MDT
View the document12.9 Referral Criteria of Leprosy Patients
Open this folder and view contents13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
Open this folder and view contents14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
Open this folder and view contents15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
Open this folder and view contents16. OTHER DISEASE CONDITIONS
Open this folder and view contents17. VIRAL INFECTIONS
Open this folder and view contents18. ALLERGIC REACTIONS
Open this folder and view contents19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
Open this folder and view contents20. MALIGNANT DISEASE CONDITIONS
Open this folder and view contents21. INJURIES AND TRAUMA
View the document22. FOREIGN BODIES
View the document23. PAIN
View the document24. POISONING
View the document25. NORMAL LABORATORY VALUES
Open this folder and view contentsNATIONAL ESSENTIAL DRUG LIST
View the documentABBREVIATIONS AND SYMBOLS
 
12.2.1 General Information about Leprosy

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). It mainly affects the skin, the peripheral nerves and the mucous membranes. It is a disease mainly of human beings, which affects people of all races, all ages and both sexes.

Patients harboring many bacilli in their bodies, the multi bacillary patients, are the main sources of infection. If not treated, they spread the disease in the community and infect others through coughing and sneezing (droplet infection). These infectious patients represent only about 25% of the registered leprosy patients in Tanzania. The other 75% of patients with few leprosy bacilli, the paucibacillary patients are less infectious. Skin contact with leprosy patients is no longer considered to be an important means of transmission.

The different manifestations of leprosy are due to differences in the degree of resistance (immunity) of the human body and not due to different kinds of bacilli.

The majority of people (about 85%) have a strong resistance to M. Leprae that even when infected they do not develop the disease. They are immune. About 75% of children who get infected with leprosy bacilli have such a high resistance that they overcome the disease themselves, without treatment, at very early stage. People who have a fairly high but incomplete immunity to leprosy bacilli will develop paucibacillary leprosy.

There are only very few people in the community (5-10%) whose immunity to M. Leprae is naturally very low. When somebody from this group of people is infected by M. Leprae, the bacilli may multiply freely and attain large numbers causing multi-bacillary leprosy.

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French